JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dibo, I.
Right arrow Articles by Segal, B. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dibo, I.
Right arrow Articles by Segal, B. H.
Journal of Clinical Microbiology, April 2004, p. 1843-1845, Vol. 42, No. 4
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.4.1843-1845.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Linezolid-Resistant Enterococcus faecalis Isolated from a Cord Blood Transplant Recipient

Imad Dibo,1 Satish K. Pillai,2 Howard S. Gold,2 Maria R. Baer,1 Meir Wetzler,1 James L. Slack,1 Peggy A. Hazamy,1 Donna Ball,1 Chiu Bin Hsiao,1 Philip L. McCarthy Jr.,1 and Brahm H. Segal1*

Department of Medicine, Roswell Park Cancer Institute, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York,1 Department of Medicine, Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard School of Medicine, Boston, Massachusetts2

Received 2 December 2003/ Returned for modification 30 December 2003/ Accepted 5 January 2004


   ABSTRACT
Top
 Abstract
Case reports
 References
 
We report a linezolid-resistant Enterococcus faecalis infection in a cord blood stem cell transplant recipient previously treated with linezolid for bloodstream infections by vancomycin-resistant enterococci. Sequencing showed a G2576U mutation in the 23S rRNA gene. Because of the important niche of linezolid in cancer treatment, linezolid-resistant E. faecalis is noteworthy.


   CASE REPORTS
Top
 Abstract
 Case reports
References
 
A 37-year-old woman underwent allogeneic cord blood stem cell transplantation as therapy for acute myeloid leukemia in second remission at Roswell Park Cancer Institute (Buffalo, N.Y.). The pretransplant course was complicated by invasive pulmonary filamentous fungal infection morphologically consistent with an Aspergillus species. The patient had a complete response to voriconazole. The posttransplant course was complicated by prolonged neutropenia and acute graft-versus-host disease (GVHD) involving skin and bowel, necessitating a prolonged course of high-dose corticosteroid therapy. Multiple courses of antibiotics were administered for persistent neutropenic fever and polymicrobial bacteremia with Klebsiella pneumoniae and a viridans group streptococcus. Six weeks after transplant, vancomycin-resistant Enterococcus gallinarum bacteremia developed and was treated initially with quinupristin-dalfopristin and then with linezolid due to hepatic toxicity associated with quinupristin-dalfopristin. Three months after transplant, the patient developed sternal chest pain and a computed tomography scan showed a lytic lesion in the sternum. A culture of a needle aspirate grew vancomycin-resistant Enterococcus faecium. The patient was treated with a 7-week course of linezolid for sternal osteomyelitis. A transthoracic echocardiogram did not show evidence of vegetations; a transesophageal echocardiogram was not performed because of mucositis associated with persistent neutropenia.

Two weeks after linezolid therapy was stopped, bilateral pulmonary infiltrates developed, and the patient required mechanical ventilation. Bronchoalveolar lavage fluid grew linezolid-resistant Enterococcus faecalis and cytomegalovirus. Treatment with foscarnet and intravenous immunoglobulinwas initiated for presumed cytomegalovirus pneumonitis. The E. faecalis isolate was considered to be a respiratory colonizer unrelated to the respiratory failure.

Further complications developed, including pancolitis associated with GVHD, colonic pseudo-obstruction, progressive liver failure (probably related to GVHD and medication-related toxicity), azotemia, and Candida glabrata cholecystitis requiring percutaneous drainage. In the setting of refractory multiorgan disease, aggressive therapy was withdrawn and the patient died.

Susceptibility testing. Despite resistance to linezolid, the E. faecalis isolate was susceptible to vancomycin, penicillins, and aminoglycosides (Table 1). The isolate showed quinupristin-dalfopristin resistance, which is a characteristic of E. faecalis. Testing for susceptibility to linezolid and quinupristin-dalfopristin was performed by disk diffusion according to NCCLS guidelines (19). The zone diameter for linezolid was 7 mm after 24 h of incubation (the cutoff diameter for susceptibility is >=21 mm). MICs of the other antimicrobial agents were determined with the Vitek system.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Antibiotic susceptibility of linezolid-resistant E. faecalis isolate

 
Sequencing the 23S rRNA gene. Genomic DNA was extracted from an overnight culture of the linezolid-resistant E. faecalis by using previously published methods (20). On the basis of sequence data from GenBank for the E. faecalis 23S rRNA gene (accession no. AJ295306), primers to amplify the domain V region were designed and optimized with Oligo primer analysis software (version 5.0; National Biosciences). The upper primer sequence was 5'-GCGGTCGCCTCCTAAAAG-3', and the lower primer sequence was 5'-ATCCCGGTCCTCTCGTACTA-3'. Following amplification with Taq DNA polymerase (Promega), the PCR product was separated by agarose gel electrophoresis and purified (QIAGEN). Sequencing of the PCR product was performed by standard dideoxynucleotide methods (Molecular Biology Core Facility, Dana-Farber Cancer Center, Boston, Mass.). Sequence data were analyzed with EditSeq (DNASTAR), MegAlign (DNASTAR), and Chromas 1.45 (Technelysium) software. The sequenced portion of the 23S rRNA gene contained the G2576U mutation (Escherichia coli numbering) previously reported to be associated with linezolid resistance (13, 14, 16, 21, 22).

Discussion. We report a case of linezolid-resistant E. faecalis isolated from a cord blood stem cell transplant recipient previously treated with a prolonged course of linezolid for infections caused by VRE. Sequence analysis showed that the 23S rRNA gene had a G2576U mutation, which is known to be associated with linezolid resistance. Linezolid is the first of a new class of synthetic antimicrobial agents, the oxazolidinones, to be approved for use in patients. Linezolid meets an important need based on its activity against virtually all clinically relevant gram-positive pathogens, including oxacillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci (VRE) (17). Linezolid is active against E. faecalis and E. faecium, whereas quinupristin-dalfopristin is active against E. faecium isolates but not against E. faecalis isolates (8). Linezolid binds to ribosomal 50S subunits, most likely within domain V within the 23S rRNA peptidyl transferase, with a secondary interaction with the 30S subunit (5). In the laboratory, strains of linezolid-resistant enterococci have been generated by serial passage of clinical VRE isolates by using doubling dilutions of linezolid; linezolid resistance was associated with mutations in the domain V region of the 23S rRNA gene (21). Clinical infections by linezolid-resistant Enterococcus species have been reported at individual centers (2, 9, 11, 13) but have been rare in the United States and internationally (3, 4, 6). The true frequency of linezolid-resistant enterococcal infections may be underestimated, because many laboratories do not routinely test enterococccal isolates for linezolid susceptibility.

Nosocomial VRE bloodstream infections are an important cause of morbidity in patients with cancer (10, 23). Outbreaks of VRE occur as a consequence of contact transmission and have been documented in cancer centers (10). Hospitalized patients with cancer may be particularly prone to VRE colonization and bloodstream infection based on multiple coexisting risk factors: the use of cephalosporins (18), the use of vancomycin and agents with anaerobic activity (7), prolonged hospitalization, neutropenia (12), and chemotherapy-induced mucositis (15). Because of the important niche of linezolid in therapy for VRE, the identification of even a single linezolid-resistant enterococcal isolate in a cancer center is noteworthy.

Cord blood transplant recipients have a higher risk of infections than other allograft recipients during the early transplant period because of slower myeloid engraftment. A significant frequency of opportunistic infections in cord blood transplant recipients after day 100 in the setting of GVHD has also been noted (1).

The linezolid-resistant E. faecalis isolate obtained from our patient was susceptible to vancomycin, penicillins, and aminoglycosides (Table 1). Linezolid-resistant enterococci are usually resistant to vancomycin and to other antimicrobial agents, though rare cases of clinical enterococcal isolates that are linezolid resistant but vancomycin susceptible have been identified (13). This finding may reflect the fact that linezolid is commonly used to treat VRE infections.

Since the initial culture of the linezolid-resistant E. faecalis in February 2002, no additional case of linezolid-resistant Enterococcus species has been identified at Roswell Park Cancer Institute. We therefore believe that in this patient linezolid-resistant enterococcal infection developed from a spontaneous G2576U mutation under the selective pressure of prolonged linezolid therapy and was not acquired from an external source. The linezolid-resistant E. faecalis isolate was recovered 15 days after treatment with linezolid was stopped, supporting the observation by Prystowsky et al. (21) that G2576U is a stable mutation that likely does not adversely affect bacterial viability.


   FOOTNOTES
 
* Corresponding author. Mailing address: SUNY at Buffalo, Division of Infectious Diseases, Roswell Park Cancer Institute, Buffalo, NY 14263. Phone: (716) 845-5721. Fax: (716) 845-3423. E-mail: brahm.segal{at}roswellpark.org. Back


   REFERENCES
Top
 Abstract
 Case reports
 References
 

  1. Alam, A. R., G. Varma, T. Hahn, B. Segal, P. Paplham, J. Becker, M. Baer, B. Bambach, J. Silva, J. Slack, M. Wetzler, and P. L. McCarthy, Jr. 2002. Infectious complications in long-term survivors of cord blood stem cell transplantation (CBSCT); experience at Roswell Park Cancer Institute. Blood 100:629(s).
  2. Auckland, C., L. Teare, F. Cooke, M. E. Kaufmann, M. Warner, G. Jones, K. Bamford, H. Ayles, and A. P. Johnson. 2002. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. 50:743-746.[Abstract/Free Full Text]
  3. Ballow, C. H., R. N. Jones, and D. J. Biedenbach. 2002. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn. Microbiol. Infect. Dis. 43:75-83.[CrossRef][Medline]
  4. Ballow, C. H., D. J. Biedenbach, F. Rossi, and R. N. Jones. 2002. Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox (R) antimicrobial potency study in Latin America (LA-ZAPS). Braz. J. Infect. Dis. 6:100-109.[Medline]
  5. Barrett, J. F. 2000. Linezolid Pharmacia Corp. Curr. Opin. Investig. Drugs 1:181-187.[Medline]
  6. Bolmstrom, A., C. H. Ballow, A. Qwarnstrom, D. J. Biedenbach, and R. N. Jones. 2002. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin. Microbiol. Infect. 8:791-800.[CrossRef][Medline]
  7. Donskey, C. J., T. K. Chowdhry, M. T. Hecker, C. K. Hoyen, J. A. Hanrahan, A. M. Hujer, R. A. Hutton-Thomas, C. C. Whalen, R. A. Bonomo, and L. B. Rice. 2000. Effect of antibiotic therapy on the density pf vancomycin-resistant enterococci in the stool of colonized patients. N. Engl. J. Med. 343:1925-1932.[Abstract/Free Full Text]
  8. Eliopoulos, G. M. 2003. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin. Infect. Dis. 36:473-481.[CrossRef][Medline]
  9. Gonzales, R. D., P. C. Schreckenberger, M. B. Graham, S. Kelkar, K. DenBesten, and J. P. Quinn. 2001. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357:1179.[CrossRef][Medline]
  10. Hanna, H., J. Umphrey, J. Tarrand, M. Mendoza, and I. Raad. 2001. Management of an outbreak of vancomycin-resistant enterococci in the medical intensive care unit of a cancer center. Infect. Control Hosp. Epidemiol. 22:217-219.[CrossRef][Medline]
  11. Herrero, I. A., N. C. Issa, and R. Patel. 2002. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N. Engl. J. Med. 346:867-869.[Free Full Text]
  12. Husni, R., R. Hachem, H. Hanna, and I. Raad. 2002. Risk factors for vancomycin-resistant Enterococcus (VRE) infection in colonized patients with cancer. Infect. Control Hosp. Epidemiol. 23:102-103.[CrossRef][Medline]
  13. Johnson, A. P., L. Tysall, M. V. Stockdale, N. Woodford, M. E. Kaufmann, M. Warner, D. M. Livermore, F. Asboth, and F. J. Allerberger. 2002. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur. J. Clin. Microbiol. Infect. Dis. 21:751-754.[CrossRef][Medline]
  14. Jones, R. N., P. Della-Latta, L. V. Lee, and D. J. Biedenbach. 2002. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 42:137-139.[CrossRef][Medline]
  15. Kuehnert, M. J., J. A. Jernigan, A. L. Pullen, D. Rimland, and W. R. Jarvis. 1999. Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect. Control Hosp. Epidemiol. 20:660-663.[CrossRef][Medline]
  16. Marshall, S. H., C. J. Donskey, R. Hutton-Thomas, R. A. Salata, and L. B. Rice. 2002. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46:3334-3336.[Abstract/Free Full Text]
  17. Moellering, R. C. 2003. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138:135-142.[Abstract/Free Full Text]
  18. Moulin, F., S. Dumontier, P. Saulnier, E. Chachaty, C. Loubeyre, L. Brugieres, and A. Andremont. 1996. Surveillance of intestinal colonization and of infection by vancomycin-resistant enterococci in hospitalized cancer patients. Clin. Microbiol. Infect. 2:192-201.[Medline]
  19. NCCLS. 2002. Performance standards for antimicrobial susceptibility testing, 12th informational supplement, vol. 22, no. 1. M100-S12. NCCLS, Wayne, Pa.
  20. Pitcher, D. G., N. A. Saunders, and R. J. Owen. 1989. Rapid extraction of bacterial genomic DNA with guanidium thiocyanate. Lett. Appl. Microbiol. 8:151-156.
  21. Prystowsky, J., F. Siddiqui, J. Chosay, D. L. Shinabarger, J. Millichap, L. R. Peterson, and G. A. Noskin. 2001. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45:2154-2156.[Abstract/Free Full Text]
  22. Woodford, N., L. Tysall, C. Auckland, M. W. Stockdale, A. J. Lawson, R. A. Walker, and D. M. Livermore. 2002. Detection of oxazolidinone-resistant Enterococcus faecalis and Enterococcus faecium strains by real-time PCR and PCR-restriction fragment length polymorphism analysis. J. Clin. Microbiol. 40:4298-4300.[Abstract/Free Full Text]
  23. Zaas, A. K., X. Song, P. Tucker, and T. M. Perl. 2002. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin. Infect. Dis. 35:1139-1146.[CrossRef][Medline]

Journal of Clinical Microbiology, April 2004, p. 1843-1845, Vol. 42, No. 4
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.4.1843-1845.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dibo, I.
Right arrow Articles by Segal, B. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dibo, I.
Right arrow Articles by Segal, B. H.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS